Drug Profile
Sufentanil transdermal - tesa Labtec
Alternative Names: Sufentanil TDSLatest Information Update: 06 Nov 2021
Price :
$50
*
At a glance
- Originator Labtec
- Developer hameln rds; tesa Labtec
- Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer pain; Pain
Most Recent Events
- 08 Mar 2017 Discontinued - Phase-I for Pain in Germany before March 2017 (Transdermal)
- 08 Mar 2017 Discontinued - Phase-II for Cancer pain in Slovakia before March 2017 (Transdermal)
- 27 Jul 2015 No recent reports on development identified - Phase-I for Pain in Germany (Transdermal)